<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132918">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02046278</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-LS-0110</org_study_id>
    <nct_id>NCT02046278</nct_id>
  </id_info>
  <brief_title>LifeSeal™ Pilot Study in Subjects Undergoing Circular Stapled Anastomosis Created Within 10 cm of the Anal Verge</brief_title>
  <official_title>LifeSeal™ Pilot Study in Subjects Undergoing Circular Stapled Anastomosis Created Within 10 cm of the Anal Verge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeBond Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LifeBond Ltd.</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pilot Study in Subjects Undergoing circular stapled anastomosis created within 10 cm of
      the anal verge.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessment of the overall Subject safety by incidence of pre specified procedure related Adverse Events.</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance Rate of anastomotic leak (both radiological and clinical leaks)</measure>
    <time_frame>Up to 15 weeks post procedure or at stoma closure, whichever comes first</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Control arm - Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The anastomosis will be created using Standard of Care only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device arm - Standard of Care + LifeSeal™ Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The anastomosis will be created using Standard of Care + LifeSeal™ Kit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifeSeal™ Kit</intervention_name>
    <arm_group_label>Device arm - Standard of Care + LifeSeal™ Kit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject, or authorized representative, signed a written Informed Consent Form

          2. Subject is 18 years or older

          3. Subject is scheduled for elective open or laparoscopic surgery involving the creation
             of a circular stapled anastomosis created within 10cm from the anal verge.

          4. If female - not be of child bearing potential, or be using acceptable contraception
             methods.

          5. Subject participating in studies involving approved drug or device will be enrolled
             only following a mutual consideration of the investigator together with the Sponsor.

        Exclusion Criteria:

          1. Subject has a history of hypersensitivity to porcine derived gelatin or collagen

          2. Subject participating in any other study involving an investigational (unapproved)
             drug or device.

          3. Subject with a BMI higher than 40

          4. Female Subject states that she is pregnant or breast feeding

          5. Subject with ASA status higher than 3

          6. Avastin use within 30 days prior to surgery

          7. Subject who underwent a prior pelvic anastomosis

          8. Subject is scheduled for another surgery during the follow up period of this study
             (not including stoma closure)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sachi Norman, Dr.</last_name>
    <phone>+972-4-6373979</phone>
    <email>Sachi@life-bond.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Van Der Speeten, Prof</last_name>
      <phone>+32-8-932-6524</phone>
      <email>Kurt.Vanderspeeten@zol.be</email>
    </contact>
    <investigator>
      <last_name>Kurt Van Der Speeten, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saskia De Groote</last_name>
      <phone>+32-9-332-4257</phone>
      <email>saskia.degroote@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Yves VanNieuiwenhove@ugent.be, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Terrasson</last_name>
      <phone>+32 16 340837</phone>
      <email>isabelle.terrasson@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Andre' D'Hoore, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anat Weizman</last_name>
      <email>anatw@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Hagit Tulchinsky, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Palmquist</last_name>
      <phone>+46-40-333742</phone>
      <email>ingrid.palmquist@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Ingvar Syk, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madelene Ahlberg</last_name>
      <phone>+46-8-51770378</phone>
      <email>madelene.ahlberg@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Anna Martling, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Lidén</last_name>
      <phone>+46 18 -611 92 26</phone>
      <email>annika.liden@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Joakim Folkesson, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Israel</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
